A083790 Stock Overview
A biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CG Invites Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,480.00 |
| 52 Week High | ₩4,385.00 |
| 52 Week Low | ₩2,015.00 |
| Beta | -0.049 |
| 11 Month Change | 4.64% |
| 3 Month Change | 1.22% |
| 1 Year Change | -7.98% |
| 33 Year Change | -63.90% |
| 5 Year Change | -75.20% |
| Change since IPO | -68.44% |
Recent News & Updates
We Think CG Invites (KOSDAQ:083790) Has A Fair Chunk Of Debt
Aug 12
CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues
Mar 19Recent updates
We Think CG Invites (KOSDAQ:083790) Has A Fair Chunk Of Debt
Aug 12CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues
Mar 19Is CrystalGenomics (KOSDAQ:083790) Using Debt Sensibly?
Jan 28
Update: CrystalGenomics (KOSDAQ:083790) Stock Gained 57% In The Last Five Years
Dec 06Shareholder Returns
| A083790 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.0% | -2.5% | -1.2% |
| 1Y | -8.0% | 40.2% | 4.8% |
Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 44.3% over the past year.
Return vs Market: A083790 underperformed the KR Market which returned 7.2% over the past year.
Price Volatility
| A083790 volatility | |
|---|---|
| A083790 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.3% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A083790 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A083790's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 77 | Joong-Myung Cho | www.cgxinc.com |
CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.
CG Invites Co., Ltd. Fundamentals Summary
| A083790 fundamental statistics | |
|---|---|
| Market cap | ₩190.70b |
| Earnings (TTM) | -₩33.92b |
| Revenue (TTM) | ₩4.56b |
41.8x
P/S Ratio-5.6x
P/E RatioIs A083790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A083790 income statement (TTM) | |
|---|---|
| Revenue | ₩4.56b |
| Cost of Revenue | ₩6.05b |
| Gross Profit | -₩1.49b |
| Other Expenses | ₩32.43b |
| Earnings | -₩33.92b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -441.16 |
| Gross Margin | -32.73% |
| Net Profit Margin | -744.20% |
| Debt/Equity Ratio | 36.4% |
How did A083790 perform over the long term?
See historical performance and comparison